Analyzing Adamis Pharmaceuticals Corporation (ADMP) & Its Peers

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is one of 111 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Adamis Pharmaceuticals Corporation to similar businesses based on the strength of its valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and profitability.

Insider and Institutional Ownership

10.0% of Adamis Pharmaceuticals Corporation shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 12.2% of Adamis Pharmaceuticals Corporation shares are held by company insiders. Comparatively, 11.7% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Adamis Pharmaceuticals Corporation has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals Corporation’s competitors have a beta of 34.21, indicating that their average share price is 3,321% more volatile than the S&P 500.

Profitability

This table compares Adamis Pharmaceuticals Corporation and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals Corporation -158.51% -69.03% -47.51%
Adamis Pharmaceuticals Corporation Competitors -2,453.12% -61.98% -8.83%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Adamis Pharmaceuticals Corporation and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals Corporation 0 0 3 0 3.00
Adamis Pharmaceuticals Corporation Competitors 858 3793 6818 185 2.54

Adamis Pharmaceuticals Corporation currently has a consensus price target of $9.83, indicating a potential upside of 116.12%. As a group, “Pharmaceuticals” companies have a potential upside of 26.03%. Given Adamis Pharmaceuticals Corporation’s stronger consensus rating and higher possible upside, equities analysts clearly believe Adamis Pharmaceuticals Corporation is more favorable than its competitors.

Valuation and Earnings

This table compares Adamis Pharmaceuticals Corporation and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Adamis Pharmaceuticals Corporation $6.47 million -$19.43 million -5.11
Adamis Pharmaceuticals Corporation Competitors $8.39 billion $1.12 billion 150.82

Adamis Pharmaceuticals Corporation’s competitors have higher revenue and earnings than Adamis Pharmaceuticals Corporation. Adamis Pharmaceuticals Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Adamis Pharmaceuticals Corporation competitors beat Adamis Pharmaceuticals Corporation on 7 of the 12 factors compared.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply